Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P. Frías, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez
Topics & Concepts
Insulin degludecMedicineMetforminType 2 diabetesInsulinDiabetes mellitusClinical endpointInternal medicineEndocrinologyPharmacologyRandomized controlled trialInsulin glargineDiabetes Treatment and ManagementGastrointestinal motility and disordersNausea and vomiting management